(NCS) — President Donald Trump lately made his boldest declare but in his longstanding promise to decrease drug prices.
“You know, we’ve cut drug prices by 1,200, 1,300 and 1,400, 1,500%,” he informed reporters on Sunday, noting the reductions will begin over the subsequent two to three months. “I don’t mean 50%. I mean 14- 1,500%.”
Trump has unveiled numerous strikes geared toward chopping drug prices in current months, however he has but to transfer the needle on lowering prices – a lot much less slashing them by 1,500%, which is mathematically not possible, specialists say.
Just how a lot Trump can be ready to accomplish is a matter of debate.
“The administration, by itself, has relatively limited power to affect drug prices across the US market,” Benedic Ippolito, a senior fellow in financial coverage research on the right-leaning American Enterprise Institute, informed NCS. “Congress has tons of power, but the administration, if they’re acting by themselves, there’s just only so much they can do.”
Still, Trump’s feedback are signaling “strong political will,” and it will be unwise for drugmakers to dismiss them, stated Milena Sullivan, coverage follow director at Avalere Health, a consulting agency with pharmaceutical corporations as shoppers.
“President Trump already has a track record of disruptive policymaking and a willingness to push the limits,” she informed NCS. “The rhetoric has only been intensifying. Even if the math doesn’t make sense, the political message is serious.”
Trump’s important effort, which he cited on August 3, facilities on getting drugmakers to provide the identical worth within the US as they do in Europe and different peer international locations, the so-called “Most Favored Nation” worth. The US paid nearly three times as a lot for medicines as did comparable international locations in 2022.
The president tried to power this coverage on the pharmaceutical business close to the tip of his first time period, finalizing a rule for a mannequin program wherein Medicare would pay the “Most Favored Nation” worth for 50 medicine administered in docs’ places of work. But the initiative was rapidly blocked in courtroom on procedural grounds and later rescinded by the Biden administration.
Now, Trump is pushing drug producers to voluntarily provide US sufferers the bottom worth paid for a drug in a peer nation or face repercussions.
“Big Pharma will either abide by this principle voluntarily or we will use the power of the federal government to ensure that we are paying the same price as other countries to accelerate these price restrictions and reductions,” the president stated in May when signing an executive order on “Most Favored Nation” pricing.
Some potential ramifications embody directing the Department of Health and Human Services to craft a rule implementing the coverage, permitting extra drug importation into the US, reviewing drug exports and having the Food and Drug Administration modify or revoke approvals granted for medicine that could be “unsafe, ineffective, or improperly marketed.”
But subsequent discussions between HHS and the drugmakers haven’t yielded the outcomes Trump desires, prompting him to publicly ratchet up the stress. He wrote letters late final month to 17 main pharmaceutical firm CEOs, which have been posted on Truth Social and skim aloud at a White House briefing.
In the letters, Trump requires producers to lengthen “Most Favored Nation” pricing to all medicine offered to Medicaid enrollees. Also, he is demanding that the businesses assure that Medicaid, Medicare and commercial-market insurers pay such prices for all new medicine.
“Moving forward, the only thing I will accept from drug manufacturers is a commitment that provides American families immediate relief from the vastly inflated drug prices and an end to the free ride of American innovation by European and other developed nations,” he wrote, giving the businesses 60 days to comply.
Asked for touch upon Trump’s declare on lowering drug prices by 1,500%, White House spokesman Kush Desai stated in an announcement to NCS, “It’s an objective fact that Americans are paying exponentially more for the same exact drugs as people in other developed countries pay, and it’s an objective fact that no other Administration has done more to rectify this unfair burden for the American people.”
Tariffs may increase prices
Trump is additionally pursuing different initiatives within the pharmaceutical business enviornment – together with tariffs, which may raise drug prices and worsen shortages of generic drugs over time. Trump excluded the business from the tariffs he imposed throughout his first time period.
The president has already agreed to the framework of a deal with the European Union, which might levy a 15% tariff on drug imports, with some exceptions for sure generic medicine. And the administration launched an investigation into nationwide safety implications of pharmaceutical imports, that are anticipated to lead to tariffs on the sector.
Trump has stated the levies – which might be as a lot as 250% however applied step by step over time – can be introduced shortly. (The EU and US have each stated that the sectoral tariffs wouldn’t apply to drug imports from Europe, however the commerce deal has but to be finalized.)
The tariffs are designed to spur extra home drug manufacturing, and Trump’s threats have prompted a bevy of pharmaceutical corporations to announce billions of dollars of investments of their US operations. But that’s nonetheless not going to present Americans with a break on their drug prices for the reason that prices they pay are largely ruled by the nation’s complicated well being system, which incorporates producers, insurers and pharmacy profit managers, often known as PBMs, specialists stated.
Trump has additionally supported PBM reform, which Congress has additionally pursued however by no means handed. And he favors having drug makers promote their sure medicines instantly to customers at “Most Favored Nation” prices, chopping out different gamers within the provide chain that may maintain prices elevated.
The administration is additionally taking a look at lowering Medicare reimbursements to sure hospitals so the funds are extra in keeping with the suppliers’ discounted acquisition prices for Part B medicine administered by docs. This would decrease sufferers’ out of pocket prices since they’re tied to Medicare’s reimbursement charges. An effort to do that in his first administration was knocked down by the Supreme Court on procedural grounds.
The extra significant insurance policies want time to implement and can possible contain different gamers within the drug provide chain, Sullivan stated.
“The political signals are that any viable solution has to tackle holistically how drugs are priced and delivered in this complex health care system,” she stated. “So it’s not just the manufacturers that are feeling some of the pressure at the moment.”
The-NCS-Wire
™ & © 2025 Cable News Network, Inc., a Warner Bros. Discovery Company. All rights reserved.